Purpose: Merkel cell polyomavirus (MCPyV) is prevalent in the general population, integrates into most Merkel cell carcinomas (MCC), and encodes oncoproteins required for MCC tumor growth. We sought to characterize T-cell responses directed against viral proteins that drive this cancer as a step toward immunotherapy.
Introduction
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer. Its reported incidence has quadrupled in the past 20 years to approximately 1,600 cases per year in the United States (1) . In 2008, the Merkel cell polyomavirus (MCPyV) was discovered and found to be integrated into the host genome in approximately 80% of MCC tumors (2) . This association of MCPyV with MCC has been confirmed by multiple groups worldwide (3) . MCPyV infection, defined by serology or detection of viral DNA, is prevalent in both healthy persons and MCC patients (4) . However, in MCC patients, MCPyV acquires oncogenic potential via rare integration and T-antigen (T-Ag) truncation mutations (5, 6) . These large T-Ag (LT) truncation mutants bind and inactivate the retinoblastoma tumor suppressor but no longer induce lytic viral replication that would be lethal to a cancer cell (7) . The small T-Ag (ST) shares the N-terminus with LT and plays an important role in activating the AKTmTOR signaling pathway (8, 9) . Importantly, MCPyV T-Ag oncoproteins are persistently expressed in MCCs and are required for growth (6, 9) .
The cellular immune system appears to be critical in preventing and controlling MCC. Patients who are chronically immunosuppressed by HIV infection, chronic lymphocytic leukemia, or medications after solid organ transplant have a 3-to 30-fold increased risk of MCC and represent approximately 10% of MCC patients (10) . There are numerous cases of spontaneous MCC regression, suggesting immune-mediated cancer control (11, 12) . Furthermore, intratumoral infiltration of CD8 lymphocytes is an independent predictor of improved survival in MCC (13) . The high prevalence of antibodies to MCPyV T-Ag (14) and VP1 capsid proteins (15) (16) (17) in MCC patients is suggestive of virus-specific helper CD4 T-cell responses.
Despite the virus dependence of most MCC tumors and the high seroprevalence of MCPyV in the general population (15) (16) (17) , there have been no reports of MCPyV-specific T-cell reactivity in MCC patients or control subjects. We hypothesized that MCPyV proteins are immunogenic and are recognized by T lymphocytes in MCC tumors and peripheral blood of patients and control subjects. Here, we show that MCPyV-specific CD8 and CD4 T cells can localize to MCC tumors and report 26 novel MCPyV T-cell epitopes, some of which may serve as targets for immunotherapy in the future.
Materials and Methods

Human subjects and clinical samples
This study was approved by the Fred Hutchinson Cancer Research Center (FHCRC) Institutional Review Board and conducted in accordance with Helsinki principles. Subjects (Supplementary Table S1 ) gave informed consent. Peripheral blood mononuclear cells (PBMC) obtained from heparinized blood samples were cryopreserved. Tumor samples obtained from medically necessary biopsies or surgeries were transported in T-cell medium (TCM; ref. 18) .
Synthetic viral peptides
A total of 428 peptides (13-mers, overlapping by 9 amino acids) were synthesized (Sigma-Aldrich; Supplementary  Table S2 ) from MCPyV reference sequence GenBank #EU375803 and strain variant #EU375804. Peptide pools ($25 peptides per pool) were organized by viral domains (Fig. 1) . Additional truncated MCPyV peptides and polyomavirus-derived homologous peptides (predicted by CLUSTAL 2.0.12 sequence alignment software) were synthesized (Supplementary Table S3 ).
Tumor-infiltrating lymphocytes culture
Minced MCC tissue was plated in 48-well plates in TCM plus 1.6 mg/mL phytohaemagglutinin (PHA; Remel), 32 units/mL natural human interleukin-2 (nIL-2; Hemagen Diagnostics), and allogeneic-irradiated PBMCs. nIL-2 in
Translational Relevance
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer (5-year disease-associated mortality rate of 46%) with limited treatment options for progressive disease. Current evidence suggests that the recently discovered Merkel cell polyomavirus (MPCyV) is causally associated with most MCCs. Reported MCC dependence on viral oncoproteins and our findings that virus-specific CD8 and CD4 T cells are present in MCC patients suggest that immunotherapeutic targeting of MCPyV and reversal of immune evasion mechanisms are promising options for patients with this disease.
The MCPyV epitopes in this report provide tools (i) to isolate both antigen-and tumor-specific T lymphocytes from blood and tumors of MCC patients, (ii) to characterize immune evasion mechanisms, (iii) to develop tumor-specific therapies such as peptide vaccines or adoptive immunotherapy, and (iv) to track T-cell responses during tumor progression or clinical trials. fresh TCM was added every second day for 14 to 20 days (18) . When conducted, a second tumor-infiltrating lymphocyte (TIL) expansion used anti-CD3 monoclonal antibody (mAb) OKT3 (Ortho), recombinant IL-2 (Chiron Corporation), and feeder cells (19) . Cultures expanded with anti-CD3 mAb are comprised entirely of CD3-Qdot655 (Invitrogen)-positive cells (Supplementary Fig. S1 ).
T-cell cloning
Subject w347 primary tumor TILs were cloned by limiting dilution and subsequently expanded (20) . Subject w347 metastatic tumor was collagenase (Sigma)-digested and plated as single-cell suspensions in TCM plus PHA and nIL-2 for limiting dilution cloning. Subject w447 bulk TILs were tetramer-sorted and expanded (19) .
ELISPOT
Cultured assays. PBMCs plated in TCM at 3 Â 10 5 cells per well in 96-well flat bottom plates were stimulated on day 1 with MCPyV peptide pools (1 mg/mL of each peptide), individual peptides (1 mg/mL), cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza peptides (CEF, 2 mg/ mL; Cellular Technology Ltd.) as positive control or dimethyl sulfoxide (DMSO; <0.2%) and/or TCM as negative control and cultured for 10 days. Fresh TCM with 20 U/mL IL-2 (Chiron Corporation) and 20 ng/mL IL-7 (R&D Systems) were added on days 3, 6, and 9. On day 11, cells were plated in 96-well multiscreen IP plate (Millipore) precoated with anti-IFN-g capture antibody (1-D1K; Mabtech). Mitogens corresponding to the prior stimulation cycle were added on day 12 and the plates developed on day 13 (21) .
Direct assays. PBMCs plated at 5 Â 10 5 cells per well in TCM were stimulated with relevant peptides. After 24 hours, plates were developed (21), scanned with an enzyme-linked immunospot (ELISPOT) reader (C.T.L.), and counted using ImmunoSpot 5.0 Software (C.T.L.). Stringent ELISPOT interpretation criteria were used to determine T-cell reactivity (Supplementary Methods).
Intracellular cytokine and flow cytometry
Responder cells stimulated with peptide in the presence of anti-CD28, anti-CD49d mAb, and brefeldin A (22) 
Cytotoxicity assay
Target cell lysis was determined by a 4-hour 51 Cr release assay in quadruplicates (25) . Negative controls included LTtransfected Cos7 plus effectors and Cos7 transfected with LT and HLA-A Ã 2402 without effectors. Positive control included detergent-lysed target cells.
Tetramer staining
PE-and APC-conjugated complexes of HLA-A Ã 2402 and peptide LT-92-101 (EWWRSGGFSF; CPC Scientific) or irrelevant peptide (NY-ESO-158-166; ref. 26) , were synthesized at the Immune Monitoring Laboratory (FHCRC, Seattle). Cells were stained with tetramer for 60 minutes at 37 C, followed by anti-CD8-APC mAb (BD Biosciences) for 30 minutes at 4 C, then washed with fluorescence-activated cell-sorting (FACS) buffer, fixed, and analyzed.
MCPyV DNA sequencing and detection DNA extraction, amplification, and sequencing are detailed in Supplementary Methods (3, 27) . Sequence data were submitted to GenBank for subjects w447 (accession number JF912157) and w347 (accession number JF912158).
HLA typing
HLA-typing genotypes from blood-derived DNA were determined by sequence-based typing of exons 2 and 3 (ref. 28 ; FHCRC, Seattle) or with commercially available (OneLambda; Qiagen) sequence-specific primer PCR kits (Puget Sound Blood Center, Seattle; Hematologisk Laboratorium, Denmark).
Immunohistochemistry
MCPyV T-Ag staining was done using CM2B4 antibody (Santa Cruz; ref. 14, 24) . Anti-CD8 (Novocastra) and anti-CD4 (Cell Marque) antibodies were used at 1:200 and 1:25 dilution, respectively.
Statistical analyses
Analyses were conducted using 2-tailed Fisher exact test in Stata v11.0 (StataCorp). A value of P < 0.05 was considered significant.
Results
To study the T-cell response to MCPyV proteins, we isolated lymphocytes from MCC tumor tissues and blood donated by MCC patients and control subjects (Supplementary Table S1 ). Fresh tumor specimens were obtained from 10 MCC patients requiring diagnostic or therapeutic surgery. TILs were successfully cultured from each tumor in sufficient numbers to test T-cell reactivity to regions of T-Ag that are persistently expressed in MCC tumors (peptide pools 1-3 and 10; Fig. 1 Iyer et al.
assay for IFN-g production to peptides from regions of T-Ag that are persistently expressed in MCC tumors (pools 1, 2, 3, and 10). A discrete population of IFN-g-secreting CD8 cells was only reactive to peptide pool 2 (Fig. 2B) . Upon challenge with single peptides from pool 2, these TILs responded to a single immunogenic peptide, LT-89-101 (KFKEWWRSGGFSF; Fig. 2B ). Truncation analysis identified a 10-amino acid section, LT-92-101 (EWWRSGGFSF), that generated strong CD8 IFN-g responses that persisted in peptide titrations to as low as 1 ng/mL ( Fig. 2B and C) . Notably, engagement of TCR signals may downregulate CD8 expression (29) , explaining slightly low CD8 signal among IFN-g-producing cells. Sequencing of DNA amplified from this patient's tumor confirmed the predicted MCPyV large T-Ag amino acid sequence (amino acids 92-101, data not shown).
We next determined whether TILs from this subject crossreacted to peptide homologues of MCPyV LT-92-101 derived from other human polyomaviruses. Cross-reactivity with other polyomaviruses could indicate T-cell priming by other pathogens prior to tumor infiltration. Conversely, if the TIL response was MCPyV specific, this would suggest that MCPyV was the relevant immunogen. To address this, we tested 13-mer peptides homologous to MCPyV LT-92-101 (Supplementary Table S3 ) and did not detect crossreactivity among TILs to these peptides (Fig. 2D) .
HLA restriction and endogenous processing of MCPyV large T-Ag
We sought to determine the restricting HLA allele from among this patient ' . This in silico prediction was confirmed using cells matched to subject w447 only at HLA-A Ã 2402. Although allogeneic partially matched PBMCs induced IFN-g secretion in CD8 TIL from subject w447, peptide-loaded PBMCs that were not matched at any HLA locus induced minimal IFN-g secretion ( Supplementary Fig. S2 ).
To study MCPyV oncoprotein processing into short peptides, we cotransfected full-length MCPyV LT and HLA-A Ã 2402 into the primate cell line Cos7 ( Fig. 2E-F ). Transfected cells were exposed to subject w447 TILs, and T-cell activation was measured by IFN-g production. Mock-transfected cells, or cells transfected with A Ã 2402 alone, did not activate subject w447 TIL. However, cotransfection of LT and A Ã 2402 led to readily detectable activation of CD8 TIL by IFN-g ICC (Fig. 2G) . Furthermore, we observed specific lysis of Cos7 cells that expressed MCPyV LT and HLA-A Ã 2402 by a TIL-derived CD8 T-cell clone ( Supplementary  Fig. S3 ). These MCPyV-specific CD8 cells also have excellent cytolytic potential against peptide-pulsed autologous cells (91% and 100% lysis of PBMCs pulsed with peptide LT.92-101 at 1 mg/mL and 5 mg/mL, respectively; Supplementary  Fig. S3 ). We conclude that (i) MCPyV LT can be processed into appropriate peptides, (ii) these peptides can access the HLA class-I antigen presentation pathway for proper loading, and (iii) MCPyV-specific CD8 TILs can recognize and kill cells expressing LT and the appropriate HLA.
MCPyV-specific CD8 T cells are enriched in the tumor as compared with blood
We synthesized a fluorescent HLA-peptide tetramer (A24: MCPyV.LT.92-101). This MCPyV-specific tetramer and a control HLA-A Ã 2402 tetramer were used to stain subject w447 PBMCs and his TILs that had been expanded in an unbiased fashion with PHA and IL-2. Our data are consistent with marked enrichment of MCPyV-specific CD8 T cells among TILs (4.0%) as compared with blood (0.14%; Fig.  3A , top and middle).
MCPyV-specific T cells identified in PBMCs in two MCC patients fail to produce IFN-g
PBMCs from 5 MCC patients (all of whom were positive for an HLA-A Ã 24xx genotype) were stained with the MCPyV tetramer. We observed a well-defined population of tetramer-bright, CD8-positive cells in PBMCs from both the index patient w447 and a second patient, w350 (Fig. 3A , middle and bottom), but not in other HLA-A24-positive or HLA-A24-negative subjects ( Supplementary Fig. S4 ). Both of these patients had T-Ag-expressing tumors. In contrast to expanded TILs from subject w447, physiologically relevant direct ELISPOT functional analyses of PBMCs from subjects w447 and w350 revealed no IFN-g production in response to antigen (Fig. 3B ). These observations were further supported by ICC assays examining IFN-g production in response to peptide among tetramer-specific cells in subject w447. Although 20% of tetramer-positive TILs secreted IFNg, only 2% of tetramer-positive PBMCs produced IFN-g ( Supplementary Fig. S5 ). The PBMCs analyzed for IFN-g were drawn during an early asymptomatic time point after recurrence (subject w447) or 1 month post-tumor removal (w350).
CD4
þ T cells with the same MCPyV specificity isolated from an MCC primary tumor and a subsequent metastasis Subject w347 was 78 years old when she presented with a 3.5-cm MCC on the right forearm. IHC revealed CD4 þ and FoxP3 þ cells within an MCPyV T-Ag protein-positive tumor (Fig. 4A ). TILs were expanded in the absence of exogenous antigen and later screened for IFN-g production to peptide pools 1, 2, 3, and 10 by the ICC assay. CD4 reactivity was observed only to peptide pool 1 (Fig. 4B ). Pool breakdown showed reactivity only to peptide CT-57-69 (TLWSKFQQNIHKL; Fig. 4B ). Of note, strong antigenic triggers may downregulate CD4 cell surface expression (31) among IFN-g-producing cells. Sequencing of MCPyV DNA amplified from tumor w347 confirmed the predicted T-Ag sequence (amino acids 57-69, data not shown).
To determine whether this CD4 TIL response was crossreactive, we tested 13-mer homologue peptides (Supplementary Table S3 ) from other human polyomaviruses. No specific reactivity to the homologous peptides was noted (Fig. 4C, left) . To investigate the nature of the CD4 response to MCPyV CT-57-69, we investigated the cytokine secretion profile of the expanded CD4 TIL population. Interestingly, we observed the secretion of both Th1 and Th2 type cytokines, namely, IFN-g, IL-5, and IL-10 ( Fig. 4C ), although the latter cytokine was only modestly increased compared with background. Moreover, 2 of 58 tested T-cell clones isolated by limiting dilution from the primary TILs also secreted IFNg and 1 of 1 clones tested also secreted IL-10 in response to peptide (Fig. 4D) .
Two months after primary tumor excision, subject w347 developed a skin recurrence of MCC (Fig. 4E, left) . After clonal microculture of the digested tumor tissue, 1 of 53 clones tested produced a robust IFN-g response to the same peptide (CT-57-69) as in the primary tumor (Fig. 4E, right) .
T-cell responses to MCPyV in the peripheral blood
PBMC reactivity was screened against the MCC-associated T-Ag oncoprotein domains (pools 1, 2, 3, and 10) in MCC patients and control subjects. We observed a trend toward a higher frequency of T-cell responses in patients than in control subjects for pool 1 (37% of patient PBMC samples vs. 8% of control subject samples), pool 2 (31% vs. 17%), and pool 10 (37% vs. 17%; Fig. 5A ). The magnitude of pool-level responses for each subject in Fig. 5A is included as Supplementary Fig. S6 . We detected PBMC responses against T-Ag in 12 of 19 patients with MCPyV-positive tumors. In contrast, we found T-Ag-specific T-cell reactivity in blood from 1 of 6 MCC patients with MCPyV-negative tumors (P ¼ 0.07).
Twenty-four additional immunogenic MCPyV epitopes were identified. Breakdown of the reactive pools to single reactive peptides is shown in Fig. 5B for 2 MCC patients and 2 control subjects. A T-cell response to a single peptide (ST-125-137) was common to both subjects C7 and w147. Responder T-cell phenotype was determined for 5 immunoreactive T-Ag-derived peptides in control subject C4 by a cultured ICC assay. In each case, the reactive cells were CD4 positive (data not shown). To explore whether these CD4 Tcell responses were likely to be MCPyV specific, we compared the sequence of the reactive MCPyV 13-mers with the homologous regions from other known polyomaviruses (Supplementary Table S3 ). Among these 5 peptides, 3 were from an MCPyV unique protein domain and 1 was sequence divergent when compared with homologous peptides, suggesting MCPyV specificity in most cases.
T-cell responses to the entire MCPyV proteome (18 peptide pools) were also assessed in 4 control subjects. PBMCs from each subject showed strong reactivity to at least 1 portion of the MCPyV proteome (Fig. 6A) . Of note, PBMCs from all 4 control subjects reacted to peptides in pool 13 (derived from the capsid protein VP1). Single peptide-level responses were deconvoluted for 2 subjects (C7 and C8). Subject C7 showed robust T-cell responses to multiple peptides within pool 13 (Fig. 6B, top) . The peptide with the strongest response (VP1-225-237) was shown to be CD4 positive (Fig. 6B, top, inset ). This particular peptide shares amino acid identity at 5 of 13 positions, with all of the homologous peptides derived from 5 other polyomaviruses (Supplementary Table S3 ). All 6 of these related peptides elicited T-cell reactivity from this subject's PBMCs (Fig. 6B , top, right). In subject C8, VP1-245-257 was the only reactive peptide within pool 13 and it stimulated CD4 cells ( bottom, inset). This immunoreactivity was MCPyV specific, as homologous peptides from other polyomaviruses were nonreactive (Fig. 6B, bottom, right) . Aggregate results for all 26 peptides described in this study are shown in Supplementary Table S4 .
Discussion
The strong association of MCC with both a polyomavirus and T-cell dysfunction suggests that dissection of the specificity, trafficking, and effector functions of MCPyV-specific T cells is medically significant. We show that circulating and tumor-infiltrating T cells can recognize specific peptides from MCPyV T-Ag oncoproteins and capsid structural proteins and that both CD8 and CD4 MCPyV-specific T cells are locally enriched in at least some MCC tumors. Twenty-six novel MCPyV T-cell epitopes have been identified. We confirmed that the T-Ag oncoprotein could be processed and presented to stimulate cell lysis by virus-specific CD8 cells isolated from a patient's tumor. We developed an MCPyV tetramer that should serve as the first of several tools for isolating and determining the function of MCPyVspecific CD8 T cells directly ex vivo. These findings advance our understanding of the association of immunosuppression with MCC and help enable rational therapies for MCC that augment virus-specific T-cell activity.
Although not previously described, several lines of evidence suggest that MCPyV-specific T cells should be present in patients and control subjects. Serologic data indicate that MCPyV infection is commonly acquired during childhood (16, 32, 33) . The presence of MCPyV-specific antibodies in 53% to 88% of healthy persons (15) (16) (17) implies the presence of MCPyV-specific CD4 T-cell help (indeed, all MCPyV-responsive T cells identified in our PBMC-based assays were CD4 þ ). Similar to these findings in MCPyV, T-cell responses have been described (34-37) in other Figure 5 . Prevalence of PBMC reactivity to MCPyV oncoproteins and determination of immunoreactive epitopes. A, PBMC T-cell reactivity (as described in ELISPOT interpretation criteria in Supplementary Methods) to specified MCPyV peptide pools among MCC patients (black) and control subjects (gray). Although there is a trend, data did not reach statistical significance. B, identification of immunoreactive epitopes derived from previously reactive T-Ag peptide pools by cultured IFN-g ELISPOT assay in MCC patients (black) and control subjects (gray). In subject C4, 5 peptides (arrows) were identified to be immunogenic to CD4 þ T cells. Iyer et al.
cancer-associated viruses, such as human papilloma virus and hepatitis C virus HCV, but are typically of low abundance (38, 39). Cultured ELISPOT or ICC assays are usually required for their detection (35, 40), but occasionally, their abundance is sufficient to be detected ex vivo by tetramers (41). Our data document significant enrichment of MCPyVspecific T cells in an MCC tumor compared with blood. In subject w447 (with a small, slow-growing tumor), we detected a marked enrichment of antigen-specific CD8 cells in TILs compared with blood using tetramer staining. Because primary tumor tissue was sparse, TILs were expanded using a nonspecific mitogen (PHA þ IL-2) cocktail that uniformly expands the peripheral T-cell repertoire (42). We therefore believe the relative frequency of antigen-specific TILs remains stable after expansion. Regardless, this finding indicates that local immune evasion mechanisms in this tumor did not block the trafficking and enrichment of virus-specific T cells. However, the tumor may persist despite these antigen-specific CD8 þ T cells due in part to low HLA-I expression. Conversely, chronic exposure to antigen may mediate an exhausted phenotype of antigen-specific CD8 þ T cells with poor effector function and sustained expression of inhibitory receptors, such as PD-1 and CTLA-4 (43). Interestingly, in subject w323 (with a large, rapidly growing tumor), we detected MCPyV T-Ag-specific T cells only in the blood but not in TILs derived from her T-Ag-expressing tumor.
In the latter case, there are several possible explanations about antigen-specific T cells: (i) they were present in the blood but failed to home to the tumor; (ii) they homed to the tumor but were undetectable because they failed to produce IFN-g; or (iii) they were present in the tumor but failed to expand in culture. It is possible that local MCPyV-specific T cells actually promoted tumor growth in some cases. Chronic antigen exposure, a common feature of MCC tumors, has been reported to induce IL-10 and IFN-g-secreting CD4 T cells that have a regulatory function (44). In subject w347, we observed MCPyV-specific IFN-g and IL-10 cytokine secretion by CD4 T cells isolated from the primary tumor. Notably, we also detected FoxP3 þ cells within the tumor microenvironment, which may be similar to the antigen-specific, IL-10-secreting, FoxP3 þ T-regulatory cell subset found to be immunosuppressive in metastatic melanoma (45). Further investigation is required to determine the role of T-regulatory cells in MCC.
There are several limitations to this study. PBMC availability prevented proteome-wide screens for some subjects; therefore, we focused on the oncogenic portions of T-Ag persistently expressed in tumors. Cultured ELISPOT assay may sometimes generate false-positive reactivity via in vitro priming (46). To eliminate such artifactual results, we used stringent ELISPOT interpretation criteria (Supplementary Methods). Finally, it was not possible to determine the extent of prior exposure to MCPyV for all studied subjects because no "gold standard" serologic or viral shedding test exists. The single most relevant indicator of MCPyV status is viral oncoprotein expression in the tumor, which was assessed for 33 of 38 patients.
In conclusion, this study is the first report of T-cell immune responses to the MCPyV. The necessary and persistent expression of T-Ags to drive MCC proliferation makes these oncoproteins especially promising targets for measuring and manipulating tumor-specific immune responses. As has been accomplished in other cancers (20, 47, 48) , the identified MCPyV T-cell epitopes may be used to design peptide-specific vaccines, to generate virus-specific T cells for adoptive immunotherapy, or to track tumor-associated antigen-specific T-cell responses.
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Supplementary Methods:
ELISPOT Interpretation Criteria. Whole data sets from a patient or a control subject were excluded from analysis if no SFU were detected from any stimulus including the positive control. A peptide pool was considered "reactive" if it contained ≥10 net SFU. Single constituent peptides from reactive pools were tested by cultured ELISPOT assay. A single peptide was considered "reactive" if both the parental pool and constituent peptide(s) showed ≥10 net SFU in the same experiment, or two separate experiments confirmed reactivity with the same peptide. Assays were excluded at the pool or single peptide level if the negative controls (DMSO or TCM) had ≥ 10 spots, or if more than 50% of peptides from a single pool had ≥ 10 net SFU due to concern for non-specific reactivity.
Plasmids. Full-length MCPyV LT was PCR-amplified from MCC tumor w156 (Genbank HM355825.1), using primers GTCGACACCATGGATTTAGTC and GCGGCCGCTTATTGAGAAAAA. The amplicon was digested with Not-I and Sal-I and cloned into similarly digested pCMV-sport6 (Invitrogen). Identity was confirmed by sequencing.
MCPyV DNA sequencing and detection. DNA was extracted using DNeasy kit (Qiagen) or QiAamp DNA FFPE Tissue kit (Qiagen) and quality assessed with a Nanodrop spectrophotometer (Thermo Scientific). 
Figure S5. Functional status of tetramer-positive CD8 T cells in tumor and blood of MCC subject w447.
Interferon-γ intracellular cytokine assay was performed using the "pre-staining" protocol described in Table S3 . Accession numbers and homologous peptides from other polyomaviruses that correspond to immunogenic MCPyV peptides. Homologous sequence alignment to MCPyV peptides using CLUSTAL (v2.0.12). Hyphens ("-") indicate there was no optimal alignment or amino acid match from the indicated polyomaviruses to the corresponding MCPyV peptide.
